vTv Therapeutics

vTv Therapeutics

vTv Therapeutics was incorporated in 2015 as a re-domiciled successor to TransTech Pharma, founded by Adnan Mjalli, and became a public entity via a $37 million IPO (per Renaissance Capital, July 2015). Headquartered in High Point, North Carolina, the company opened with a portfolio of oral small-molecule drug candidates targeting the GLP-1 receptor, the receptor for advanced glycation end-products (RAGE), and the glucokinase activator mechanism. From the outset, vTv inherited a broad pipeline of molecules originally discovered in the labs of TransTech Pharma, providing a head start on conditions with substantial unmet medical need, including type 1 diabetes, Alzheimer's disease, and inflammatory disorders. The company's strategy focuses on repositioning and repurposing small molecules with established safety profiles. Its lead asset, cadisegliatin (TTP399), an oral, liver-selective glucokinase activator, advanced into a pivotal Phase 3 trial for type 1 diabetes with breakthrough therapy designation from the FDA (per the firm, June 2022). In neurology, azeliragon (TTP488), a RAGE antagonist, underwent Phase 2/3 trials for mild Alzheimer's disease. vTv benefits from significant non-dilutive funding structures, including a 2020 partnership with the Juvenile Diabetes Research Foundation (JDRF) that covered a substantial portion of development costs for cadisegliatin in type 1 diabetes (per JDRF, October 2020). The company has also collaborated with GSK, the National Institute on Aging, and the Alzheimer's Disease Cooperative Study to fund and operationalize clinical trials across the United States and China. Paul Sekhri, appointed CEO in April 2023, brought decades of biotech operational and dealmaking experience from Sanofi, Teva, and Novartis, signaling a pivot toward late-stage execution (per the firm, April 2023). The firm's scale is lean, consistent with a clinical-stage platform seeking strategic exits rather than building an internal commercialization engine. Most clinical operations are outsourced to contract research organizations. The company carved out a subsidiary, vTv Therapeutics LLC, and in 2017 issued a convertible note facility with a MacAndrews & Forbes affiliate to fund operations. The firm's ability to sustain a Phase 3 program without a massive internal sales force illustrates its capital-efficient, partnership-reliant architecture. vTv's structural differentiator lies in its origin as a molecule-repository spinout. Unlike discovery-stage biotechs that burn cash on target identification, vTv inherited a library of roughly 3 million compounds and the core TTP Translational Technology Platform from TransTech Pharma, giving it a proprietary chemical-entity backbone (public record). This legacy asset base, paired with a public-company structure, allows vTv to fund clinical trials through equity and grants rather than venture capital alone, creating a hybrid funding model uncommon among micro-cap biotechs targeting central nervous system and metabolic diseases.